The Next Frontier of Cellular Therapy in Oncology
ONCOLOGY · 28.10.2026 · 40 (7)
DOI: 10.46883/2026.25921245 ↗Kurz gefasst
Fachartikel in der Zeitschrift ONCOLOGY, online erschienen am 28.10.2026. Verfasst von Anas Zayad und 1 weiteren Autor:innen. Hauptthemen laut MEDLINE: Neoplasms, Immunotherapy, Adoptive, Cell- and Tissue-Based Therapy.
Abstract (Originalsprache)
The National Immune Cell Effector Therapy (ICE-T) Symposium convened on September 27, 2025, in Kansas City, Kansas, bringing together hematologists, oncologists, nurses, and researchers to address the rapidly evolving landscape of immune effector therapies. Sessions spanned chimeric antigen receptor (CAR) T-cell therapy and bispecific T-cell engagers, with emphasis on their expanding role in multiple myeloma, lymphomas, and, increasingly, autoimmune diseases such as systemic lupus erythematosus. Presenters explored both the clinical promise and the practical challenges of these therapies across a wide range of settings. Collectively, the meeting underscored a shift toward making cellular therapy safer, more scalable, and more equitably accessible.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Zayad, A., & Awadallah, C. (2026). The Next Frontier of Cellular Therapy in Oncology. ONCOLOGY, 40(7). https://doi.org/10.46883/2026.25921245
Vancouver
Zayad A, Awadallah C. The Next Frontier of Cellular Therapy in Oncology. ONCOLOGY. 2026;40(7). doi:10.46883/2026.25921245
BibTeX
@article{Zayad2026,
author = {Zayad, Anas and Awadallah, Carmel},
title = {The Next Frontier of Cellular Therapy in Oncology},
journal = {ONCOLOGY},
year = {2026},
volume = {40},
number = {7},
doi = {10.46883/2026.25921245}
}
EUVIMED